Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 2, 2026

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Small-cell lung cancer.

Jan P van Meerbeeck1, Dean A Fennell, Dirk K M De Ruysscher

  • 1Department of Respiratory Medicine and Lung Oncological Network, Ghent University Hospital, Ghent, Belgium. jan.vanmeerbeeck@ugent.be

Lancet (London, England)
|May 14, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improved organs-of-interest dose reduction potential with intensity modulated proton therapy and breath-hold in mediastinal lymphoma.

Physics and imaging in radiation oncology·2026
Same author

Evolutionary characterization of lung cancer metastasis.

Nature·2026
Same author

Assessing the impact of proton versus photon therapy on health-related quality of life in lung cancer.

Clinical and translational radiation oncology·2026
Same author

Mesothelioma: a systemic therapy clinical trials snapshot.

Trends in cancer·2026
Same author

Photon-counting CT for radiotherapy: Qualitative assessment of potential clinical value by semi-structured expert interviews.

Clinical and translational radiation oncology·2026
Same author

Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment.

Lung cancer (Amsterdam, Netherlands)·2026

Small-cell lung cancer (SCLC) presents a global health challenge with limited treatment options upon relapse. Research is exploring new drug targets within identified signaling pathways to improve patient outcomes.

Area of Science:

  • Oncology
  • Pulmonology
  • Cancer Research

Background:

  • Small-cell lung cancer (SCLC) is a significant global health concern due to its high incidence and mortality rates.
  • Diagnosis typically involves histology and immunohistochemistry, with characteristic patient profiles including older male smokers with comorbidities.
  • SCLC often presents with rapid symptom onset due to tumor growth, metastasis, or paraneoplastic syndromes.

Purpose of the Study:

  • To summarize the current understanding of small-cell lung cancer diagnosis, staging, and treatment.
  • To highlight the challenges in managing SCLC, particularly regarding treatment resistance and relapse.
  • To identify potential new therapeutic avenues through the exploration of signaling pathways.

Main Methods:

  • Review of diagnostic criteria, including histology and immunohistochemistry.

Related Experiment Videos

Last Updated: Jun 2, 2026

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

  • Analysis of staging systems for classifying SCLC as metastatic or non-metastatic.
  • Examination of current first-line treatment strategies for SCLC, including chemotherapy and radiotherapy.

    • Main Results:

    • SCLC requires a multidisciplinary approach involving chemotherapy (platinum-based with etoposide or irinotecan) and radiotherapy.
    • Prophylactic cranial irradiation is recommended for patients with no disease progression post-treatment.
    • Despite initial high response rates, SCLC frequently relapses, with limited salvage treatment options.

    Conclusions:

    • Current SCLC treatments, while effective initially, are often followed by relapse, necessitating novel therapeutic strategies.
    • Identified signaling pathways in SCLC offer promising targets for the development of new drugs.
    • Further research into these pathways is crucial for improving long-term survival and treatment efficacy in SCLC patients.